My Portfolio transactions have been limited the past few months. However, I ratcheted those up in the first half of July.
Over the course of a few days, I made 5 transactions involving 5 different stocks. I added to 3 existing holdings and trimmed a couple of holdings, too.
The moves started with an addition to one of my smallest holdings. This was followed by a trim of a stock I haven’t traded since I established my position years ago, and a trim of a stock where I unloaded my most expensive shares. I then bought some shares of a stock that’s recently down on its luck, and a closed-end fund that help me recoup my lost income… and then some.
After all the moves were done, I ended up making a net withdrawal, even though I boosted my income a bit.
Here are the details for my latest Portfolio transactions…
Salesforce (CRM)
CRM was my 3rd smallest holding at the time I added to my position. It was a case of deciding to either make it a larger position, or eliminate it from my Portfolio. Given that CRM is a Tech stock, and that I’m always trying to find such stocks for my Portfolio, I wasn’t ready to give up on it just yet.
CRM joined my Portfolio only 4 months ago, and this was my first time growing the position since then. With the stock trading for a price below the level at which I started my position, adding a few shares to average down was easy to do.
On 7/11/25, I bought 5 shares of CRM at $258.00/share, for a total cost of $1,290.00. The stock yielded 0.64% at my purchase price, which is not even 1/4 of my current Portfolio yield of 2.70%. However, it is slightly higher than its own 5-yr. average yield of 0.58%.
My CRM share total climbed by 33.28% with this purchase, and my share total became 20.024 shares. Given CRM’s low yield, my annual forward dividend income rose by only $8.32 with the purchase.
This purchase also lowered my cost basis some. It decreased by $3.49/share, to $268.49/share.
CRM climbed five spots in my Portfolio rankings thanks to my purchase, becoming my 8th smallest position in the process. CRM now trails the Walt Disney Co. (DIS) in my Portfolio rankings.
Despite the addition, CRM remains a small part of my Portfolio, and it’s a holding that still needs to get larger. A further dip below $250 would be a good level to consider another purchase.
Main Street Capital (MAIN)
Here’s a stock that has been a solid contributor to my Portfolio over the course of several years. I initiated my position in MAIN just over 9 years ago. I hadn’t bought or sold any shares since that time… only reinvested dividends.
My position had nearly doubled thanks to those reinvested dividends, from the 100 shares I initially bought to just a tad over 196 shares.
Unfortunately, MAIN reached overvalued territory for me, so I decided to lighten up my position and make sure this high-yielder didn’t become too large of a position for my Portfolio.
On 7/14/25, I sold 96 shares of MAIN at $63.15/share. I basically sold nearly all of my reinvested dividends. I got to keep all the sale proceeds of $6,062.40 since SEC fees for stock sales have been eliminated for the remainder of Fiscal Year 2025.
At my sale price, shares of MAIN yielded 4.85%. This is more than 2 percentage points above my current Portfolio yield.
With this sale, I realized a long-term capital gain of $1,980.46 and a short-term capital gain of $121.92. Sadly, my annual forward dividend income dropped by a whopping $293.76.
Nearly half of my MAIN position was sold. I still have 100.83 shares of MAIN left after a recent reinvested dividend. With the trim, the cost basis of my shares dropped by $4.20/share to $32.66/share.
MAIN tumbled down my Portfolio rankings as a result of the trim. The sale took my 22nd largest holding and made it into my 46th largest holding. The stock is sandwiched in between Medtronic (MDT) and Hershey Co. (HSY) now.
I don’t suspect I’ll be adding or selling MAIN shares anytime soon. The position should grow naturally if I just reinvest the dividends like I have been doing.
NNN REIT (NNN)
I’ve been looking to sell my most expensive NNN shares for a little while now, at least 6 months. While I don’t want to necessarily make my NNN position smaller, I thought I might be able to unload these shares and potentially buy them back at a lower price.
If the price never dipped again, then I’d be OK with the lighter position. Well, NNN climbed in price over the past 7 months and finally crept over the $43.80 price I was looking for. So, I made the sale. We’ll see if I add them back at a lower price in the future.
On 7/14/25, I sold my most expensive 13 shares of NNN at $43.81/share. The sale proceeds were $569.53 after not having to pay an SEC fee.
At my sale price, shares of NNN yielded 5.30%. This is nearly double my current Portfolio yield of 2.70%.
With this sale, I realized a tiny long-term capital gain of $0.26. My annual forward dividend income fell by $30.16, though.
About 12.5% of my NNN position was sold. I still have 90.38 shares of NNN, which have a cost basis of $40.75/share. This was a decline of roughly $0.38/share.
The sale of NNN didn’t change the Portfolio ranking of the stock at all. It was my 4th smallest holding and remained there. If I’m going to buy back these NNN shares, I’ll target a share price below $42, but more preferably, below $40.
Accenture (ACN)
While not as small of a position as CRM was, ACN fit the bill as another Tech stock in my Portfolio that deserved to be bigger.
ACN has declined over $100/share since February. Weak bookings and future growth concerns are issues contributing to the drop. IT consulting is facing challenges, including rising talent costs. There’s also the emergence of AI, which has some ACN clients feeling they can tackle their business transformations independently.
The current price of ACN is not much higher than when I established my position back in December 2022. So, I decided to add a few shares while they are looking less expensive than normal.
On 7/15/25, I bought 5 shares of ACN at $277.00/share, for a total cost of $1,385.00. The stock yielded 2.14% at my purchase price. While this is less than my current Portfolio yield, it’s higher than ACN’s 5-year average yield of 1.46%.
My ACN share total rose by 24.23% with this purchase, and my share total now stands at 25.633 shares. My annual forward dividend income increased by a decent $29.60.
The purchase raised my cost basis in ACN. It climbed by $2.05/share to $268.57/share.
Despite my ACN purchase being fairly modest, ACN rose nine spots in my Portfolio rankings as a result of my buy. It’s now my 19th smallest position. It sits behind Lockheed Martin (LMT), and is slightly ahead of UGI Corp. (UGI).
Adding more ACN is a strong possibility, especially should the stock test the $260 level. I’ll keep the stock on my radar.
PIMCO Corporate & Income Strategy Fund (PCN)
After conceding a good chunk of dividend income with my MAIN sale from earlier, I wanted to recoup that.
So, I targeted an additional purchase of PCN after I initiated my position in the closed-end fund just last month.
With the huge yield of PCN, I could replace that lost income and still have cash left over… which I’d probably squirrel away with retirement looming.
PCN is largest a multi-sector bond fund, so boosting the size of PCN added some additional diversification to my stock Portfolio.
In addition, PCN had declined a bit in price since I initiated my position, so it was nice to boost my position while lowering my cost basis.
On 7/15/25, I bought 265 shares of PCN at $12.54/share, for a total cost of $3,323.10. The fund yielded 10.77% at my purchase price, which is nearly 4x my current Portfolio yield of 2.70%.
My PCN position size jumped by more than 66% with this purchase, and my share total has settled at exactly 665 shares. My annual forward income soared by $357.75 with the share addition.
As noted earlier, this purchase lowered my cost basis a bit. It slipped by one nickel per share, to $12.62/share.
PCN launched eighteen spots up my Portfolio rankings as a result of my purchase. It moved from my 7th smallest position to my 25th smallest position. PCN now trails UnitedHealth Group (UNH) in my Portfolio rankings, but leads fellow closed-end fund BlackRock Health Sciences Trust (BME).
I’m open to adding more PCN shares. I’ll look for a price drop to the $12.40 level in the short-term.
Summary
I managed to execute a handful of Portfolio transactions in the 1st half of July. This ended what had been a fairly quiet couple of months for transactions.
All totaled, I made 5 moves – 3 purchases of existing holdings, and 2 partial sales.
The purchases included small additions to a pair of Tech stocks (CRM & ACN), the trim of a position that got overvalued in my mind (MAIN), the trim of a position where I wanted to unload my most expensive shares (NNN) and the purchase of a closed-end fund that recouped my lost income while diversifying my Portfolio at the same time (PCN).
The transactions resulted in a net withdrawal from my Portfolio of $633.83. However, my forward dividend income increased by $71.75 due to the high yield of PCN.
With the MAIN and NNN sales, I realized a total long-term capital gain of $1,980.72 and a short-term capital gain of $121.92.
With the two sales just being trims, and the buys being stocks already in my Portfolio, the number of holdings in my Portfolio remained at 60.
Have you been trading any stocks recently? What was the motivation to buy or sell? Did the transactions alter your Portfolio in any sort of meaningful way? I look forward to your comments!